Is it reasonable to rely on individual scientists to monitor the dual-use potential of their own work?
7
Should there be rules regarding the use of genetic manipulation technologies like RNAi?
8
Given the rapid advancement and specialization of biotechnology research, is it realistic to expect the NSABB and other institutional review bodies to take on responsibility for dual-use issues?
9
What responsibility should researchers take for dual-use research? How about companies?